Papers/PMID:27770542
Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies.
British journal of clinical pharmacology2017The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
sertraline — increases congenital cardiovascular malformation incidence (offspring)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Pregnant women who used sertraline in the first trimester had a statistically significant increased risk of infant cardiovascular-related malformations (OR = 1.36; 95% CI = 1.06-1.74; I2 = 64.4%; n = 12) as well as atrial and/or ventricular septal defects (OR = 1.36, 95% CI = 1.06-1.76; I2 = 62.2%; n = 8).”
Quoted verbatim from Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies.. - Study
- meta-analysis
- Population
- Infants of pregnant women exposed to sertraline in the first trimester; meta-analysis of 12 cohort studies
Effect 1.36 odds ratio, 95% CI 1.06 to 1.74
Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies.2017PMID:27770542Permalink